Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Genovese

Showing results (51-60 of 172) with videos related to

Pageof 18
Sort By:
American Journal of Obstetrics and Gynecology|June 23, 2005
Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosusEliza F Chakravarty, Iris Colón, Elizabeth S Langen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 30, 2023
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid ArthritisMatthew C Baker, Sarah Kavanagh, Stanley Cohen, et al.
Annals of the Rheumatic Diseases|July 26, 2011
Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trialPhilip G Conaghan, Paul Emery, Mikkel Østergaard, et al.
Arthritis Care & Research|September 14, 2012
Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice studyMichael E Weinblatt, Joel Kremer, John Cush, et al.
Annals of the Rheumatic Diseases|December 27, 2012
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitorsMark C Genovese, Roy M Fleischmann, Maria Greenwald, et al.
Rheumatology (Oxford, England)|July 28, 2018
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2Mark C Genovese, Benard Combe, Joel M Kremer, et al.
The Lancet. Rheumatology|January 27, 2024
Targeting GM-CSF in rheumatological conditions: risk of PAP - Authors' replyMark C Genovese, Christopher D Buckley, Didier Saurigny, et al.
Arthritis Research & Therapy|March 29, 2020
Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritisMark C Genovese, Juan Sanchez-Burson, MyungShin Oh, et al.
BMC Rheumatology|March 20, 2019
Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritisAnne C Bay-Jensen, Adam Platt, Martin A Jenkins, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2015
Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group StudyMark C Genovese, Katerina Jarosova, Dorota Cieślak, et al.
Pageof 18

Showing results (51-60 of 172) with videos related to

Sort By:
Pageof 18
American Journal of Obstetrics and Gynecology|June 23, 2005
Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosusEliza F Chakravarty, Iris Colón, Elizabeth S Langen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 30, 2023
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid ArthritisMatthew C Baker, Sarah Kavanagh, Stanley Cohen, et al.
Annals of the Rheumatic Diseases|July 26, 2011
Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trialPhilip G Conaghan, Paul Emery, Mikkel Østergaard, et al.
Arthritis Care & Research|September 14, 2012
Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice studyMichael E Weinblatt, Joel Kremer, John Cush, et al.
Annals of the Rheumatic Diseases|December 27, 2012
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitorsMark C Genovese, Roy M Fleischmann, Maria Greenwald, et al.
Rheumatology (Oxford, England)|July 28, 2018
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2Mark C Genovese, Benard Combe, Joel M Kremer, et al.
The Lancet. Rheumatology|January 27, 2024
Targeting GM-CSF in rheumatological conditions: risk of PAP - Authors' replyMark C Genovese, Christopher D Buckley, Didier Saurigny, et al.
Arthritis Research & Therapy|March 29, 2020
Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritisMark C Genovese, Juan Sanchez-Burson, MyungShin Oh, et al.
BMC Rheumatology|March 20, 2019
Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritisAnne C Bay-Jensen, Adam Platt, Martin A Jenkins, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2015
Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group StudyMark C Genovese, Katerina Jarosova, Dorota Cieślak, et al.
Pageof 18